Antivirals with clinical potential.
D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D006560:Herpes Labialis / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007251:Influenza, Human / Q000628:therapy; D007542:Inosine Pranobex / Q000627:therapeutic use; D007369:Interferon Inducers / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007635:Keratitis, Dendritic / Q000188:drug therapy; D007978:Levamisole / Q000627:therapeutic use; D008720:Methisazone / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D012899:Smallpox / Q000628:therapy; D014740:Vidarabine / Q000627:therapeutic use
D000998:Antiviral Agents; D007369:Interferon Inducers; D003561:Cytarabine; D007978:Levamisole; D012254:Ribavirin; D007372:Interferons; D000547:Amantadine; D014740:Vidarabine; D008720:Methisazone; D007065:Idoxuridine; D007542:Inosine Pranobex